Axon Enterprise, Inc. (NASDAQ:AXON) Receives Consensus Rating of “Buy” from Brokerages

Shares of Axon Enterprise, Inc. (NASDAQ:AXON) have received a consensus recommendation of “Buy” from the thirteen analysts that are presently covering the company, MarketBeat.com reports. Thirteen analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $460.33.

AXON has been the topic of several analyst reports. The Goldman Sachs Group increased their price target on Axon Enterprise from $385.00 to $441.00 and gave the company a “buy” rating in a report on Wednesday, October 23rd. Northland Securities increased their price target on Axon Enterprise from $365.00 to $550.00 and gave the company an “outperform” rating in a report on Monday, November 11th. Morgan Stanley upgraded Axon Enterprise from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $500.00 to $700.00 in a report on Tuesday. JMP Securities increased their price target on Axon Enterprise from $430.00 to $500.00 and gave the company a “market outperform” rating in a report on Thursday, October 31st. Finally, Needham & Company LLC increased their price objective on Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a research report on Friday, November 8th.

Axon Enterprise Trading Up 0.3 %

Shares of AXON stock opened at $689.78 on Friday. Axon Enterprise has a 12 month low of $231.83 and a 12 month high of $695.94. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. The business’s 50 day moving average is $504.47 and its two-hundred day moving average is $387.43. The company has a market cap of $52.60 billion, a PE ratio of 178.24, a price-to-earnings-growth ratio of 14.74 and a beta of 1.01.

Insider Buying and Selling

In related news, President Joshua Isner sold 25,811 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $359.84, for a total value of $9,287,830.24. Following the completion of the transaction, the president now directly owns 228,166 shares of the company’s stock, valued at $82,103,253.44. This trade represents a 10.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jeffrey C. Kunins sold 8,182 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $364.86, for a total value of $2,985,284.52. Following the completion of the transaction, the insider now directly owns 176,228 shares of the company’s stock, valued at approximately $64,298,548.08. This trade represents a 4.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 137,921 shares of company stock valued at $63,093,907 over the last ninety days. 6.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Park Avenue Securities LLC increased its stake in shares of Axon Enterprise by 7.2% in the second quarter. Park Avenue Securities LLC now owns 4,326 shares of the biotechnology company’s stock valued at $1,273,000 after buying an additional 291 shares in the last quarter. CWM LLC increased its stake in shares of Axon Enterprise by 1.5% in the second quarter. CWM LLC now owns 2,820 shares of the biotechnology company’s stock valued at $830,000 after buying an additional 43 shares in the last quarter. QRG Capital Management Inc. increased its stake in shares of Axon Enterprise by 9.1% in the second quarter. QRG Capital Management Inc. now owns 2,539 shares of the biotechnology company’s stock valued at $747,000 after buying an additional 212 shares in the last quarter. Czech National Bank increased its stake in shares of Axon Enterprise by 8.8% in the second quarter. Czech National Bank now owns 13,518 shares of the biotechnology company’s stock valued at $3,978,000 after buying an additional 1,097 shares in the last quarter. Finally, Artemis Investment Management LLP increased its stake in shares of Axon Enterprise by 3.7% in the second quarter. Artemis Investment Management LLP now owns 96,867 shares of the biotechnology company’s stock valued at $28,502,000 after buying an additional 3,453 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.